

## Sibeprenlimab

Cat. No.:	HY-P99901
CAS No.:	2382896-07-1
Molecular Weight:	146.36 kDa
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) <sup>[1][2][3]</sup> .
<b>In Vitro</b>	Sibeprenlimab (VIS649, 10, 50 µg/mL, 5 d) inhibits APRIL-mediated proliferation of Na ve (CD43-) mouse B cells and survival of RPMI 8226 and JJN3 <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Sibeprenlimab (VIS649, 0.5-25 mg/kg/week, i.v., 4-8 weeks) selectively reduces serum IgA levels of Cynomolgus monkeys <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Mohit Mathur, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. *Kidney Int Rep.* 2022 Feb 8;7(5):993-1003.
- [2]. Mathur M, et al. A Proliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. *J Clin Med.* 2023 Nov 4;12(21):6927.
- [3]. Refardt J, et al. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. *N Engl J Med.* 2023 Nov 16;389(20):1877-1887.
- [4]. Myette JR, et al. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. *Kidney Int.* 2019 Jul;96(1):104-116.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA